Last reviewed · How we verify

NCT00651378

Switching to Rosuvastatin Versus Adding Ezetimibe to Atorvastatin Versus Doubling the Dose of Atorvastatin in Patients With Hypercholesterolemia and Risk Factors (P03708)

Terminated Phase 4 Last updated 15 August 2024
What this trial tests

Phase 4 trial testing Rosuvastatin in Hypercholesterolemia in 87 participants. Terminated before completion.

Timeline
1 September 2004
Primary endpoint
1 June 2005
1 June 2005

Quick facts

Lead sponsorOrganon and Co
PhasePhase 4
StatusTerminated
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposetreatment
Enrollment87
Start date1 September 2004
Primary completion1 June 2005
Estimated completion1 June 2005

Drugs / interventions tested

Conditions studied

Sponsor

Organon and Co — full company profile →

Who can join

Adults 18 to 75, any sex, with Hypercholesterolemia or Atherosclerosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study assesses whether adding ezetimibe 10 mg/d to ongoing treatment with atorvastatin 10 mg/d is more effective than switching the subject to treatment with rosuvastatin 10 mg/d or doubling the dose of atorvastatin to 20 mg/d is more effective in achieving goal LDL-cholesterol of \<2.5 mmol/L. Treatment phase is 6 weeks.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Rosuvastatin

Trials testing the same drug.

Other recruiting trials for Hypercholesterolemia

Currently open trials in the same condition.

Other Organon and Co trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00651378.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing